Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1990-06-04
1991-11-26
Friedman, Stanley J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514516, A61K 3121, A61K 3126, A61K 31415
Patent
active
050682407
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to antitumour pharmaceutical compositions and process for preparing the same. Another object of the present invention is the use of certain polyamine derivatives having a molecular weight of not higher than 800 in the therapy of diseases connected with cellular proliferation.
BACKGROUND ART
Compounds of the general formula ##STR2## are known in the literature and used in many different industrial fields. Thus, e.g. N-[2-[2-(heptadecenyl)-2-imidazolin-1-yl]-ethyl]-oleamide is known from GB Pat. No. 929,397 as additive for polyepoxydbitumens. J. Chem. Res. Synop. 1981/3/84-5 and DE-OS No. 2,546,180 disclose the reactions of different steric isomers of N-[2-[2-(8-heptadecenyl)-4,5-dihydro-1H-imidazol-1-yl]-ethyl]-9-octadecena mide and the use thereof in the floatation of Nb/Ta minerals. The article of Przem. Chem. 46/8/, 479-81 describes the (1:1) mixture of N,N'-[ethylenebis(iminoethylene)]bis(9,11-octadecadienamide) and -(9,11-octadecadienoate) and the use thereof as cationic surfactant. According to U.S. Pat. No. 3,337,459 N,N'-[iminobis(ethyleneiminoethylene)]bis(10-octadecenamide) is used as lubricant. U.S. Pat. No. 3,193,454 describes 1,1'-(iminodiethylene)bis[2-(heptadecenyl)-2-imidazoline as additive for paints.
There is, however, no reference at all in the prior art to any therapeutical effect of the aforementioned compounds.
The last 100 years brought basic changes in the human environment, especially as a result of the extraordinary development of chemistry. Of course, this development started in unfavourable phenomena as well, and one of these is the rapid increase of tumorous diseases.
At present, cancer research is one of the most developing research areas and needs extraordinary financial and mental supply. Besides basic research, there are great efforts in the therapy of certain specific types of tumorous diseases. In many cases, chirurgical intervention is often accomplished by other kinds of therapy, e.g. irradiation, chemotherapy, etc. The known processes and especially chemotherapeutic methods have the common characteristics that they are limited in the field of specific types of tumour. No general method resulting in a general regeneration of tumorous cells has been found so far.
According to the present state of science, tumorous diseases can be cured when detected in the very early state. As the early phase is very hard to recognize, tumorous diseases belong to those which are the most difficult to cure. Generally, symptomatic treatment is performed but the recovery rate is very poor. Therefore, there is a strong need for therapeutic agents which prevent the occurance of tumorous diseases and provide general and appropriate therapeutic effect in case of developed disease at the same time.
DISCLOSURE OF INVENTION
The aim of the present invention is to provide pharmaceutical compositions which fulfills the above conditions. There is also provided a process for preparing the same pharmaceutical compositions.
A further object of the present invention is the use of the compounds of the general formula (I) as above in and for the therapy of tumorous diseases.
The invention is based on the recognition that the reason of starting of cancerous processes is due to failures in the correct information and/or circulation chain between cells. In healthy organ, permanent communication takes place between the cells. The occurance of malign processes in the organ is a result of lack of "communication channels" between cells, as the cells cannot recognize each other, lose their connections and start of multiply according to their own internal information. The multiplication is of malign degree and leads to proliferation.
It has been found that the proliferated cells having occured due to malign processes are not to be destroyed, but the possible contact between these and/or healthy cells should be re-established. The only way to re-establish the tissue structure of tumour cells into healthy tissue is to renew the intercellular communication.
Presumably
REFERENCES:
patent: 3085940 (1963-04-01), Cufcik et al.
LandOfFree
Antitumor pharmaceutical compositions and process for preparing does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antitumor pharmaceutical compositions and process for preparing , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antitumor pharmaceutical compositions and process for preparing will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2386075